OptiBiotix Health

TICKER: OPTI     EXCHANGE: AIM

OptiBiotix Health PLC has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression.

LATEST REPORTS

 
More than a Gut feeling...
Published: Jul 08 2015

We are pleased to make available a research note from Peterhouse Research on OptiBiotix Health:
OptiBiotix Health PLC (OPTI) has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression.
Results from a clinical trial on cholesterol reduction should be available in the final quarter of 2015. This product concept is a 'must-have' for major players in functional food, and OPTI recently signed a placeholder option agreement with a multinational consumer goods company.
The main research programme is to build an OptiBiotics platform and develop novel 'oligosaccharides' as 'microbiome modulators'. The target is to fuel the growth of a proprietary microbial strain/s to help modulate population surges in 'good' gut (or other localised) bacteria and derive well-evidenced health benefits - potentially a market in excess of $1bn.
OPTI is a virtual company, focusing on its R&D whilst out-sourcing clinical trials, manufacturing and downstream activities. The aim is to license its product and microbial strain IP, or have product supply agreements with appropriate partners, in order to develop a robust royalty income stream. 
A preliminary sales- and royalty-based model suggests a DCF valuation up to £50m, nearly twice the current market cap. Positive news and a future differentiated OptiBiotic portfolio with multiple disease-specific products could achieve a multiple of this. 
 
OptiBiotix Health - ED Investor Forum 24th June 2015
Published: Jun 24 2015

Stephen O'Hara, CEO, presents on behalf of OptiBiotix Health plc.

ARCHIVE

Foreign buyers gorging on UK stocks

Document can be downloaded here: UK plc ‘going for a song’

Being a shareholder in a company that receives a juicy takeover offer is a marvellous feeling. Something that many fortunate investors have experienced over the past 3 years. Thanks to a spate of M&A bids by deep pocketed overseas buyers – partly triggered by the June 2016 Brexit result, which sent the £ tumbling and adversely affected the FTSE.

Consequently today, given this trend is unlikely to end anytime soon, we’ve highlighted 30 possible acquisition ideas in the attached research paper. Spilt equally between large and smallcap stocks – covering a broad selection of industries.

What’s more we believe most of these businesses are underpinned by strong fundamentals and substantial upside in the event of predatory interest.

According to Factset Mergerstat/BVR, the average bid premium paid for such deals between 2004-14 was 30% – with the figure trending upwards since the global financial crisis.

Happy investing. Published 27th August 2019